The snake venom peptide sarafotoxin S6b inhibits repetitive XXXX formation in the stenosed @entity235 coronary artery.

@entity11976 @entity1423 @entity235 @entity117 @entity1426 @entity715 @entity850
Various snake venom peptides have been extensively evaluated for use as antithrombotic agents. Recently, it was determined that the snake venom peptide sarafotoxin S6b (S6b) is structurally similar to the potent vasoactive hormone @entity11976 ( @entity11976 ), which has been shown to inhibit agonist-induced @entity1423 . The potential in vivo antithrombotic activity of S6b was compared with that of @entity11976 , a much more potent pressor agent than S6b, by evaluating the effects of S6b and @entity11976 (0.5 microgram/kg i.v.) on repetitive @entity1423 formation (RPTF) in the stenosed @entity235 circumflex coronary artery. In this model platelets adhere to the damaged vessel wall near a mechanically produced @entity850 . As platelets aggregate at this site, blood flow gradually declines until the vessel is completely occluded. The @entity715 is then physically dislodged, thus restoring flow. The blood flow pattern resulting from RPTF is referred to as cyclic flow reductions (CFRs). Injection of S6b or @entity11976 blocked RPTF, as indicated by inhibition of CFRs. On a rating system of 0 (no effect) to 3 (complete inhibition), S6b and @entity11976 produced CFR ratings of 1.8 +/- 0.5 (n = 6) and 2.0 +/- 0.4 (n = 6), respectively. This effect was not blocked by pretreatment with @entity117 at 5 mg/kg i.v., a dose that abolishes @entity1426 -induced ex vivo @entity1423 (CFR scores for S6b and @entity11976 were 2.6 +/- 0.2, n = 5 and 2.0 +/- 0.3, n = 5, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
